发明名称 |
Pharmaceutical formulation comprising ezetimibe |
摘要 |
The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 μm to 35 μm and d(0.5) of 3 μm to 20 μm, as well as methods for preparing said formulations. |
申请公布号 |
US8858994(B2) |
申请公布日期 |
2014.10.14 |
申请号 |
US200812747270 |
申请日期 |
2008.12.09 |
申请人 |
Ratiopharm GmbH |
发明人 |
Gat Ganesh;Giridhara Rao Pasupuleti;Hussain Javed |
分类号 |
A61K45/00;A61K45/06;A61K9/20;A61K31/397 |
主分类号 |
A61K45/00 |
代理机构 |
Smith Patent |
代理人 |
Smith Chalin A.;Smith Patent |
主权项 |
1. A pharmaceutical composition comprising:
5 to 20 wt-% ezetimibe particles (1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone), 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 2 to 5 wt-% solubility enhancer 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant,wherein the ezetimibe particles have a particle size distribution characterized by a d(0.9) value of 9 μm to 20 μm and a d(0.5) value of 3 μm to 50 μm. |
地址 |
Ulm DE |